Nonalcoholic steatohepatitis: The therapeutic challenge of a global epidemic

Current Opinion in Lipidology

Volumn 22, Issue 6, 2011, Pages 479-488

  Schattenberg, Jörn M ^a   Schuppan, Detlef ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

fibrogenesis, fibrosis; inflammation; insulin resistance; lipotoxicity; liver; nonalcoholic fatty liver; nonalcoholic steatohepatitis; oxidative stress; treatment

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; DOCOSAHEXAENOIC ACID; FATTY ACID; LOSARTAN; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID;

APOPTOSIS; CLINICAL TRIAL (TOPIC); DIET; DRUG RESEARCH; EPIDEMIC; EXERCISE; FIBROGENESIS; HUMAN; IMMOBILIZATION; INSULIN RESISTANCE; LIPOLYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVERNUTRITION; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; WEIGHT REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BILE ACIDS AND SALTS; DIET, REDUCING; EPIDEMICS; FATTY LIVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 81855213130     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32834c7cfc     Document Type: Review

References (99)

1. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40:1461-1465.
2. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51:1961-1971.
3. Bellentani S, Marino M. Epidemiology and natural history of nonalcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8 (Suppl 1):S4-S8.
4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274-285.
5. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011; 26 (Suppl 1):163-172.
6. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43:S99-S112.
7. Calori G, Lattuada G, Ragogna F, et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011; 54:145-152.
8. Fabbrini E, Magkos F, Mohammed BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106:15430-15435.
9. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; [Epub ahead of print]. doi: 10.1002/hep.24491
10. Baumeister SE, Volzke H, Marschall P, et al. Impact of fatty liver disease on healthcare utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134:85-94. (Pubitemid 350309322)
11. Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40 (Suppl 1):S39-S43. (Pubitemid 44309542)
12. Schuppan D, Gorrell MD, Klein T, et al. The challenge of developing novel pharmacological therapies for nonalcoholic steatohepatitis. Liver Int 2010; 30:795-808.
13. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52:774-788.
14. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-1374. (Pubitemid 46918320)
15. Schattenberg JM, Wang Y, Singh R, et al. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005; 280:9887-9894. (Pubitemid 40395836)
16. Schattenberg JM, Schuchmann M. Diabetes and apoptosis: liver. Apoptosis 2009; 14:1459-471.
17. Missiou A, Wolf D, Platzer I, et al. CD40L induces inflammation and adipogenesis in adipose cells: a potential link between metabolic and cardiovascular disease. Thromb Haemost 2010; 103:788-796.
18. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008; 14:1225-1230. (Pubitemid 351997835)
19. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50:957-969.
20. Goodpaster BH, Delany JP, Otto AD, et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA 2010; 304:1795-1802.
21. Kistler KD, Brunt EM, Clark JM, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011; 106:460-468.
22. Tilg H, Moschen A. Weight loss: cornerstone in the treatment of nonalcoholic fatty liver disease. Minerva Gastroenterol Dietol 2010; 56:159-167.
23. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009; 50:1294-1306.
24. Poelstra K, Schuppan D. Targeted therapy of liver fibrosis/cirrhosis and its complications. J Hepatol 2011; 55:726-728.
25. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128:1898-1906. (Pubitemid 40824701)
26. Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44:874-880. (Pubitemid 46489551)
27. Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 2010; 52:370-381.
28. Centis E, Marzocchi R, Di Domizio S, et al. The effect of lifestyle changes in nonalcoholic fatty liver disease. Dig Dis 2010; 28:267-273.
29. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for nonalcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; (1): CD007340. doi: 10.1002/14651858. CD007340.pub2.
30. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the longterm effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137:532-540.
31. Newton JL. Systemic symptoms in nonalcoholic fatty liver disease. Dig Dis 2010; 28:214-219.
32. Krasnoff JB, Painter PL, Wallace JP, et al. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2008; 47:1158-1166.
33. Zelber-Sagi S, Kessler A, Brazowsky E, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4:639-644.
34. Stensel D. Exercise, appetite and appetite-regulating hormones: implications for food intake and weight control. Ann Nutr Metab 2010; 57 (Suppl 2):36-42.
35. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab 2011; 96:1093-1097.
36. Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Gut 2011; [Epub ahead of print]. doi: 10.1136/gut.2011.242016
37. Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr 2011; 53:131-140.
38. Schattenberg JM, Wang Y, Rigoli RM, et al. CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology 2004; 39:444-455. (Pubitemid 38222185)
39. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53:1883-1894.
40. He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285:6706-6715.
41. Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42:132-138. (Pubitemid 40038911)
42. Calderon RM, Cubeddu LX, Goldberg RB, et al. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 2010; 85:349-356.
43. Ekstedt M, Franzen LE, Mathiesen UL, et al. Statins in nonalcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47:135-141. (Pubitemid 46817693)
44. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011; 106:71-77.
45. Trebicka J, Hennenberg M, Odenthal M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010; 53:702-712.
46. Cheung O, Kapoor A, Puri P, et al. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 2007; 46:1091-1100. (Pubitemid 350144773)
47. Tamimi TI, Elgouhari HM, Alkhouri N, et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011; 54:1224-1229.
48. Phillips SA, Kung JT. Mechanisms of adiponectin regulation and use as a pharmacological target. Curr Opin Pharmacol 2010; 10:676-683.
49. Mao G, Kraus GA, Kim I, et al. A mitochondria-targeted vitamin E derivative decreases hepatic oxidative stress and inhibits fat deposition in mice. J Nutr 2010; 140:1425-1431.
50. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol 2011; 54:1244-1249.
51. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
52. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305:1659-1668.
53. Torres D, Jones F, Shaw J, et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis (NASH): a 12 month-randomized, prospective, open-label trial. Hepatology 2011; [Epub ahead of print]. doi: 10.1002/hep.24558
54. Rakoski MO, Singal AG, Rogers MA, et al. Meta-analysis: insulin sensitizers for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2010; 32:1211-1221.
55. Sugii S, Evans RM. Epigenetic codes of PPARgamma in metabolic disease. FEBS Lett 2011; 585:2121-2128.
56. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135:100-110. (Pubitemid 351916703)
57. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355:2297-2307. (Pubitemid 44837778)
58. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675-1685.
59. Mahady SE, Webster AC, Walker S, et al. The role of thiazolidinediones in nonalcoholic steatohepatitis: a systematic review and meta analysis. J Hepatol 2011; [Epub ahead of print]. doi: 10.1016/j.jhep.2011.03.016
60. Seino Y. Understanding the incretin effect. J Clin Endocrinol Metab 2011; 96:934-935.
61. Martin JH, Deacon CF, Gorrell MD, et al. Incretin-based therapies: review of the physiology, pharmacology and emerging clinical experience. Intern Med J 2011; 41:299-307.
62. Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007; 6:242-250.
63. Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011; 60:1246-1257.
64. Gross BN, Cross LB, Foard J, et al. Elevated hepatic enzymes potentially associated with sitagliptin. Ann Pharmacother 2010; 44:394-395.
65. Tam J, Liu J, Mukhopadhyay B, et al. Endocannabinoids in liver disease. Hepatology 2011; 53:346-355.
66. Massa F, Mancini G, Schmidt H, et al. Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. J Neurosci 2010; 30:6273-6281.
67. Cluny NL, Vemuri VK, Chambers AP, et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 2010; 161:629-642.
68. Nakagami H, Kiomy OM, Nakagami F, et al. Prevention and regression of nonalcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. Int J Mol Med 2010; 26:477-481.
69. Sugimoto K, Qi NR, Kazdova L, et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47:1003-1009. (Pubitemid 44297575)
70. Bataller R, Gabele E, Parsons CJ, et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005; 41:1046-1055. (Pubitemid 40593912)
71. Georgescu EF, Ionescu R, Niculescu M, et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated nonalcoholic steatohepatitis. World J Gastroenterol 2009; 15:942-954.
72. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40:1222-1225. (Pubitemid 39425579)
73. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371:838-851. (Pubitemid 351323895)
74. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134:1655-1669. (Pubitemid 351615417)
75. Tetri LH, Basaranoglu M, Brunt EM, et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008; 295:G987-G995.
76. Kohli R, Kirby M, Xanthakos SA, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010; 52:934-944.
77. Leclercq IA, Sempoux C, Starkel P, et al. Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. Gut 2006; 55:1020-1029. (Pubitemid 43962616)
78. Kaji K, Yoshiji H, Kitade M, et al. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am J Physiol Gastrointest Liver Physiol 2011; 300:G1094-G1104.
79. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006; 12:671-676. (Pubitemid 43865236)
80. Higuchi H, Gores GJ. Bile acid regulation of hepatic physiology. IV: Bile acids and death receptors. Am J Physiol Gastrointest Liver Physiol 2003; 284:G734-G738. (Pubitemid 36437972)
81. Pathil A, Warth A, Chamulitrat W, et al. The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNFalpha-induced liver injury. J Hepatol 2011; 54:674-684.
82. Ratziu V, De Ledinghen V, Oberti F, et al. A randomized controlled trial of highdose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011; 54:1011-1019.
83. Beraza N, Ofner-Ziegenfuss L, Ehedego H, et al. Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. Gut 2011; 60:387-396.
84. Koppe SW, Sahai A, Malladi P, et al. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 2004; 41:592-598. (Pubitemid 39297794)
85. Zein CO, Yerian LM, Gogate P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 10:277-286.
86. Van Wagner LB, Koppe SW, Brunt EM, et al. Pentoxifylline for the treatment of nonalcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011; 10:277-286.
87. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321. (Pubitemid 40770284)
88. Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11:560-565. (Pubitemid 28280720)
89. Moscatiello S, Di Luzio R, Bugianesi E, et al. Cognitive-behavioral treatment of nonalcoholic Fatty liver disease: a propensity score-adjusted observational study. Obesity (Silver Spring) 2011; 19:763-770.
90. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51:121-129.
91. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in nonalcoholic fatty liver disease. Gut 2009; 58:1281-1288.
92. Hussein O, Grosovski M, Schlesinger S, et al. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci 2007; 52:2512-2519. (Pubitemid 47373883)
93. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51:445-453.
94. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19:537-544. (Pubitemid 38387180)
95. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100:1082-1090. (Pubitemid 40769045)
96. Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009; 43:990-994.
97. Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008; 57:1711-1718.
98. Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4:1537-1543. (Pubitemid 44880031)
99. Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with nonalcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011; 96:350-353.